Home » Navigo and Mannin Ink Deal to Develop COVID-19 Treatment
Navigo and Mannin Ink Deal to Develop COVID-19 Treatment
German biotech Navigo Proteins is teaming up with the German subsidiary of Ontario, Canada-based Mannin Research to develop Mannin’s investigational recombinant protein as a treatment for patients with COVID-19.
Specifically, the protein is designed to activate an enzyme that plays a role in blood vessel formation and maintenance which may improve patient outcomes with severe infections including COVID-19.
Navigo will be providing Mannin with its technology for purification of proteins for use in manufacturing the potential final drug product.
The financial terms of the deal were not disclosed.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May